Note issued to Arcion Therapetuics, Inc., dated May 18, 2009



 Exhibit 10.91 
 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE, PLEDGE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 
 THIS NOTE IS SUBJECT TO THE TERMS AND CONDITIONS OF THE PURCHASE AGREEMENT (AS DEFINED BELOW). 
 NOTE 
  

			
	 $2,000,000.00
	  	May 18, 2009

 For value received, Anesiva, Inc., a Delaware corporation (the “Company”),
promises to pay to the order of Arcion Therapeutics, Inc. (together with its successors and assigns, the “Holder”), the principal sum of Two Million Dollars ($2,000,000), together with interest accrued but unpaid thereon, upon the
terms of this Note (the “Note”). 
 Interest shall accrue from the date hereof until maturity at a continuously compounding
rate equal to ten percent (10%) per annum payable in cash; provided, however, that, during the occurrence and continuance of an Event of Default (as defined in that certain Secured Note Purchase Agreement, dated as of May 18,
2009 (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), among the Company and the Holder), interest shall accrue at a continuously compounding rate equal to fourteen percent
(14%) per annum. All computations of interest shall be made on the basis of a year of 365 or 366 days, as the case may be, for the actual number of days (including the first day but excluding the last) occurring in the period for which such
interest is payable. 
 Unless earlier paid pursuant to the terms hereof or the Purchase Agreement or accelerated in connection with an Event
of Default, subject to the terms of the Purchase Agreement, the outstanding principal and accrued but unpaid interest shall be immediately due and payable on October 20, 2009 (the “Maturity Date”). Company may prepay this Note
at any time without penalty or premium. 
 1. This Note is issued pursuant to the terms of the Purchase Agreement. The Holder is entitled to
the benefit of, and is subject to certain restrictions contained in, the Purchase Agreement and the other Related Documents. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement. The
indebtedness evidenced by this Note is secured by certain collateral, as more particularly described in that certain Pledge, Security and Collateral Agent Agreement, dated as of May 18, 2009 (as may be further amended, restated, supplemented or
modified from time to time, the “Security Agreement”), among the Company, AlgoRx Pharmaceuticals, Inc. and the Collateral Agent and that certain Guaranty, dated as of January 20, 2009 (as may be further amended or modified from
time to time, the “Guaranty”) by and between AlgoRx Pharmaceuticals, Inc. and the Holder. 








 
Each holder of this Note will be deemed, by its acceptance hereof, to have agreed to the provisions and to have made the representations and warranties set
forth in Section 4 the Purchase Agreement. Subject to the terms of the Purchase Agreement, this Note is transferable by surrender hereof at the principal office of the Company, duly endorsed or accompanied by a written instrument of transfer
duly executed by the registered holder of this Note or by any other method permitted by the Purchase Agreement. 
 2. All payments hereunder
shall be applied in the order provided for in the Purchase Agreement. Whenever any payment hereunder shall be stated to be due, or whenever any return payment date or any other date specified hereunder would otherwise occur, on a day other than a
Business Day, then such payment shall be made, and such return payment date or other date shall occur, on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest
hereunder. 
 3. All payments in respect of this Note shall be in immediately available lawful money of the United States of America and
shall be sent so as to be received no later than 2 p.m. (Pacific time) on the date of payment, at the address specified in the Purchase Agreement, or at such other address as may be specified from time to time by such Holder in a written notice
delivered to the Company. All payments in respect of this Note shall be made unconditionally in full without any deduction, set off, counterclaim or other defense. If any scheduled payment date is not a Business Day, such payment shall be made on
the next succeeding Business Day. 
 4. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 
 5. (a) The terms of this Note shall be construed in accordance with the laws of the State of California, as applied to contracts entered into by
California residents within the State of California, which contracts are to be performed entirely within the State of California. The Company hereby (i) submits to the exclusive jurisdiction of the courts of the County of San Francisco, State
of California and the Federal courts of the United States sitting in the Northern District of the State of California for the purpose of any action or proceeding arising out of or relating to this Note, the Purchase Agreement and the Related
Documents; (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such courts; (iii) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may
have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum; and (iv) agrees
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. 
 (b) The parties agree that any dispute, controversy or claim (including any counterclaim) (each, a “Dispute”) arising out
of or relating to this Note, the Purchase Agreement or any Related Documents shall be finally resolved by confidential binding arbitration in San Francisco County, California as the sole and exclusive method of resolving such dispute, controversy or
claim. Any Dispute shall be settled by arbitration under the rules then in effect of JAMS/Endispute conducted by a single arbitrator reasonably acceptable to the parties. The arbitrator shall have no power to amend this Note, the Purchase Agreement
or any Related 

  

 2 








 
Documents. The arbitrator shall issue an award in writing (including an explanation of the grounds for such award) as promptly as practicable that shall be
final and binding on the parties. Judgment upon any award thus obtained may be entered in any court having jurisdiction thereof. No action at law or in equity based upon any claim arising out of or related to this Note, the Purchase Agreement or any
Related Documents shall be instituted in any court by any party except (a) an action to compel arbitration pursuant to this Section 5(b); or (b) an action to enforce an award obtained in an arbitration proceeding in accordance with
this Section 5(b). Pending the submission to arbitration and thereafter until the arbitrator publishes its award, each party shall, except in the event of termination, continue to perform all its obligations under this Note, the Purchase
Agreement and the Related Documents without prejudice to a final adjustment in accordance with the award. 
 6. Notwithstanding any provision
of this Note to the contrary, any payments hereunder deemed to be interest shall not exceed the maximum rate permitted by applicable law. To the extent that any interest otherwise paid or payable by the Company to the Holder shall have been finally
adjudicated to exceed the maximum amount permitted by applicable law, such interest shall be retroactively deemed to have been a required repayment of principal (and any such amount paid in excess of the outstanding principal amount shall be
promptly returned to the Company). 
 7. Any term of this Note and the other Securities may be amended and the observance of any term of this
Note and the other Securities may be waived (either generally or in a particular instance and either retroactively or prospectively), only in accordance with the terms of the Purchase Agreement. Any such amendment or waiver shall be effective only
for the specific instance and for the specific purpose for which given. 
 8. No remedy herein conferred upon the Holder is intended to be
exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every right or other remedy now or hereafter existing at law or in equity or by statute or otherwise. 
 9. No course of dealing between the Company and the Holder or any delay on the part of the Holder in exercising any rights or remedies shall operate as a
waiver of any such right or remedy of the Holder. 
 10. This Note shall be binding on and inure to the benefit of and be enforceable by the
Company, the Holder and their respective successors and assigns. The Company may not assign, transfer, hypothecate or otherwise convey its rights, benefits, obligations or duties hereunder without the prior express written consent of the Majority
Investors. Any such purported assignment, transfer, hypothecation or other conveyance by the Company without the prior express written consent of the Majority Investors shall be void. 
 11. Whenever possible, each provision of this Note shall be interpreted in such manner as to be effective and valid under all applicable laws and
regulations. If, however, any provision of this Note shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or
regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Note, or the validity or effectiveness of
such provision in any other jurisdiction. 
  

 3 








 12. This Note is issued pursuant to the Purchase Agreement and in connection with the Security Agreement,
the Pledge Agreement and the other Related Documents. Material terms applicable to this Note are set forth in the Purchase Agreement, the Security Agreement, the Pledge Agreement and the other Related Documents. This Note shall be interpreted in a
manner to give full effect to its provisions and the provisions of the Purchase Agreement, the Security Agreement, the Pledge Agreement and the other Related Documents. 
 13. The Company agrees to pay on demand all costs and expenses of the Holder, and the reasonable fees and disbursements of its counsel (including the allocated costs of internal counsel), in connection with:
(i) any amendments, modifications or waivers of the terms hereof or of the Purchase Agreement or of any other Related Documents; (ii) the protection or preservation of the Holder’s rights under this Note, under the Purchase Agreement
or under any other Related Documents, whether by judicial proceeding or otherwise; (iii) enforcement or attempted enforcement of, and preservation of any rights under, this Note, the Purchase Agreement or any other Related Documents;
(iv) creating, maintaining and perfecting Liens in favor of the Collateral Agent, for the benefit of the Holder, including filing and recording fees and expenses, and (v) any out-of-court workout or other refinancing or restructuring or in
any bankruptcy case, including, without limitation, any and all losses, costs and expenses sustained by the Holder as a result of any failure by the Company to perform or observe its obligations contained herein or in the Purchase Agreement or in
any of the other Related Documents. 
 [Remainder of page intentionally left blank] 
  

 4 








 This Note has been issued in reliance upon the representations and warranties and covenants and
agreements of the Company and the Holder set forth in the Purchase Agreement. 
  

			
	ANESIVA, INC.
		
	By:	 	/s/ Michael L. Kranda
	Name:	 	Michael L. Kranda
	Title:	 	President and CEO


  

			
	Accepted and Agreed:
	
	ARCION THERAPEUTICS, INC.
		
	By:	 	/s/ James N. Campbell, M.D
	Name:	 	James N. Campbell, M.D.
	Title:	 	Chief Executive Officer

 [SIGNATURE PAGE TO SECURITY]